Geron Corporation · NASDAQ:GERN
Geron — Stifel Healthcare Conference 2014
14 slides from Geron's conference presentation, Nov 18, 2014
Slide 1: Stifel Healthcare Conference 2014
Stifel Healthcare Conference 2014 eron John Scarlett, M Chief Executive Officer nber 19, 2014
Slide 2: Forward-looking statements
a forward-looki Ng statements xcept for the histo! nformatin contained heen, this presentation contains forwardoking statements made pursuant to the “sale harbor” provstons ofthe Private Secures LMgation Ror Act of 1995. Investor are ‘autoned that ‘statements in ths presentation regarding: () the an
Slide 3: Geron: well-positioned for future growth
es Geron: well-positioned for future growth ‘© Imetelstat: a novel and transformative oncology product candidate = first telomerase inhibitor in clinical development = demonstrated disease-modifying activity in ET (ASH 2012) and MF (ASH 2013) = mechanism of action suggests broad activity across hema
Slide 4: Imetelstat: a telomerase inhibitor
geron imetelstat a telomerase inhibitor Telomerase enzyme: (© adds nucleotide repeats to offset the loss of telomeric DNA occurring with each replication cycle © not active in somatic cells; transiently upregulated in normal hematopoietic progenitor cells to maintain telomeres and support controlled
Slide 5: Hematologic myeloid malignancies with high unmet medical need
geron hematologic myeloid malignancies with high unmet medical need + arise from malignant progenitor cell clones in bone marrow + express higher telomerase activity compared to normal cells, + limiting proliferation of malignant progenitors with imetelstat suggests disease-modifying activity Myelof
Slide 6: Preliminary efficacy data suggest transformative potential
geron preliminary efficacy data suggest transformative potential © Proof-of-concept study in essential thrombocythemia ~ compelling and durable hematologic responses ~ significant and exceptional molecular responses suggested inhibition of malignant progenitor cell clones in relatively selective man
Slide 7: Patient (prior Jak inhibitor): bone marrow complete remission on imetelstat
ee patient 2 (prior Jak inhibitor): bone marrow complete remission on imetelstat Baseline (1/28/ 5.5-months post imetel: [ie ie 0 eating ara eect)
Slide 8: Efficacy data suggest differentiated activity in MF
geron efficacy data suggest differentiated activity in MF Pf Arma (n= 11) | ArmB (n= 11) | Total (n= 22) Best Response by 2013 IWG criteria N(%) N(%) N(%) Overall Response (CR+PR+Cl) 3 (27.3%) 6 (54.5%) 9 (40.9%) Remission (CR+PR) 2 (18.2%) 3 (27.3%) 5 (22.7%) ‘Complete Remission (CR) 2 (18.2%)? 1(9
Slide 9: Remissions observed suggest disease-modifying activity in MF
remissions observed in data suggest disease-modifying activity in MF all manifestations of disease must be addressed in patients to achieve a remission [| se a Normal cellularity and reversal of bone marrow fibrosis 5 Normal peripheral blood counts and smears voev v x v a i Anemia response or transf
Slide 10: Preliminary safety data indicate myelosuppression is dose-limiting toxicity
geron preliminary safety data indicate myelosuppression is dose-limiting toxicity © Proof-of-concept study in essential thrombocythemia - cytopenias most frequently reported adverse event - mild-to-moderate non-hematologic adverse events (gastrointestinal events and fatigue) ~ persistent low-grade l
Slide 11: Partnership with Janssen
eee partnership with Janssen yanssen Jr exclusive worldwide collaboration for imetelstat t Stage Continuation Stage Final Read Out Phase Za Study ‘Phase MF, MOS Phase2:Addional exploratory ineatlons Phase 2.5:AML Phase 2 Low Rsk MOS (RARS) Study + Jansen to execute Phase 2 MF and Phase 2 = Gerom has
Slide 12: Upcoming events
geron upcoming events © ASH Annual Meeting (December 2014) ~ oral presentation on updated Myelofibrosis Pilot Study safety and efficacy data ~ oral presentation on analysis of calreticulin (CALR) allelic burden in ET patients ~ poster presentations on imetelstat mechanism of action in MF and imetels
Slide 13: Geron: well-positioned for future growth
geron Geron: well-positioned for future growth © Imetelstat: a novel and transformative oncology product candidate ~ first telomerase inhibitor in clinical development ~ demonstrated disease-modifying activity in ET (ASH 2012) and MF (ASH 2013) ~ mechanism of action suggests broad activity across he
Slide 14: Thank you
thank you For further information, please contact: Kevin Eng, Ph.D., Investor Relations +1.650.473.776